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This study has carried out a mini-review on first wave of COVID-19 infection and its control by the
Kurdistan Regional Government (KRG)/Iraq. COVID-19 infection, which was named by the International
Committee of Taxonomy of Viruses (ICTV) as SARS-CoV-2, is a newly identified coronavirus. The last
century has seen the outbreak of numerous life-threatening human pathogens including Nipah, Ebola,
Zika, Chikungunya, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory
syndrome coronavirus (SARS-CoV), and more recently a novel coronavirus has been observed. COVID-19
infection has so far spread to more than 186 countries around the world and KRG/Iraq has not been free
from this virus. In this survey, the control of COVID-19 infection in KRG as a part of Iraq is discussed in
detail. The methods of identification as well as the drugs that are currently in common use to reduce the
wide distribution of COVID-19 infection and their effects in countries around the world are considered.
So far, 714 positive cases have been reported by the ministry of health in Kurdistan Region Government-
Iraq (KRG), among which there have been only 8 deaths, and 420 cases have recovered. Those who died
had a previous history of a chronic disease such as diabetes, hypertension, heart disease, and hyper-
cholesteremia. Alternative medicine based on natural green methods has been widely used by Kurdish
people in past years for treatment of strong coughs. In the present study, some natural products which
are cost free and effective in enhancing the body's resistance against the virus are considered. A sur-
prising finding is that the patients in KRG have not in general had a severe cough, flu, or fever. The
possible explanation may relate to the patients' strong immune systems, since none of them had a
history of using alcohol and drugs, or of chronic disease. The epidemiology and transmission of the virus
are discussed as well.
© 2020 University of Sulaimani. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).College of Medicine, Univer-
laymaniyah, Iraq.
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Coronaviruses are members of the Coronaviridae family and
under electron microscope observation have the appearance of
spiked rings; the viruses have different types of spikes on their
surface that are used to attack and bind living cells, as shown in
Fig. 1 [1,2].l Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Cross-sectional model of a coronavirus showing the Glycoprotein spikes, M-
Protein, E Protein and Hemagglutinin-esterase dimer on the surface of the virus.
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Taxonomy of Viruses (ICTV) as SARS-CoV-2, is a newly identified
coronavirus infection in humans that causes outbreaks of respira-
tory illness. This recent COVID-19 infection was recognized as a
serious public health threat by the US Centers for Disease Control
and Prevention (CDC). The first case of this novel coronavirus
infection was identified on December 30, 2019 in Hubei province,
Wuhan city, China and subsequently it spread globally [3]. Recently
(March 2020), the World Health Organization (WHO) recognized
this infection, which can induce severe pneumonia, as a pandemic
viral disease after identification of huge numbers of cases in Iran,
Italy, Spain, France, Germany, and other European countries and the
USA and globally the numbers are rising every day [3,4].
Coronaviruses represent a large family of enveloped RNAviruses
found in a broad range of animals including birds, camels, cattle,
cats, and bats. It has beenwidely reported that this new coronavirus
spread from animals to humans with continued circulation
resulting from human-to-human exposure. Initially, COVID-2019
patients were shown to have some link to a large seafood and
live animal market in Wuhan, China, suggesting animal-to-person
transmission. However, subsequent cases appear to have resulted
from human-to-human contact as more recent patients have not
been exposed to animal markets [4,5].
COVID-2019 is the third coronavirus to emerge in the human
population in the past two decades, preceded by the SARS-CoV
outbreak in 2002 and the MERS-CoV outbreak in 2012. This has
put global health institutions on high alert. The CDC andWHO have
developed a preparedness and prevention checklist for COVID-2019
infection for use by the public and healthcare professionals [6].
At present, no antiviral medication or vaccine is available for
treating COVID-2019 infection. Infected patients are managed with
supportive care, although some medications, alone or in combi-
nation with other drugs, have been suggested [7,8].
2. Infection
Coronaviruses cause numerous diseases that affect the gastro-
intestinal and respiratory tract in humans and other mammals [1].
Mammalian cells become a battlefield when infected by these vi-
ruses, with cells providing antiviral defenses against the infectious
virus, produced as a reaction to the infecting virus, and the end
outcome of this battle is a major determinant of the pathogenesis
[9,10]. The coronavirus's structure consists of a single-stranded
positive-sense RNA that possesses a large viral RNA genome
which is similar to the genomic organization of other beta-coronaviruses [7]. The general signs of infection include respira-
tory problems, fatigue, muscle pain, high fever, sneezing, sore
throat and dry cough [1]. SARS-CoV-2 coronavirus, like other vi-
ruses, infects lung alveolar epithelial cells and produces symptoms
such as flu, fever, dry cough, difficult respiration, pneumonia, and
death [8].
3. Identification
Detection of coronavirus in patients with pneumonia was car-
ried out by testing bronchoalveolar lavage fluid, chest CT radiog-
raphy, cell culture, polymerase chain reaction (PCR). Then the virus
was isolated from biological samples to identify the genus, and
compared to Severe Acute Respiratory Syndrome (SARS) and Mid-
dle East Respiratory Syndrome (MERS) [10]. Genetic analysis of
COVID-19 showed that the virus was very similar to Severe Acute
Respiratory Syndrome Coronavirus (SARS-CoV) [11]. WHO guid-
ance provided on March 2, 2020 for laboratory testing of corona-
virus diseases mentioned that suspected cases of infection should
be screened and tested for the virus by using nucleic acid amplifi-
cation tests (NAAT) such as RT-PCR.
4. Transmission
Patients with the coronavirus infection were in the beginning
period of the infection asymptomatic, or transfer from direct con-
tacts could cause a moderate illness. The contagious period could
be up to three weeks and patients could develop a severe illness
[12]. No evidence on the difference in severity of COVID-19 pneu-
monia was found between male and females, while pregnant
women with pneumonia are considered more likely than non-
pregnant women to die from the infection [13,14].
Shahabinezhad et al. reported on the age distribution of deaths
among patients infected with COVID-19, and they found that the
highest number of deaths was among infected people aged be-
tween 60 and 80 years, constituting 26.4% of infected people in that
age range. Whereas, there were far fewer deaths (2.3% of patients)
in the age range 10e50 years, and no deaths were recorded among
patients of less than 10 years of age. Even though mild clinical
symptoms were observed in children in comparison with adults,
children should receive more protection and isolation [15,16].
5. Treatments
No specific antiviral drugs or vaccines are yet available for the
treatment of this unanticipated and fatal pathogen. Supportive care
and non-specific treatment to improve the symptoms of the patient
(especially the fever) are the only alternative therapies [17]. To
reduce the effect of COVID-19 infection, scientists are looking to
find a new drug to eradicate the virus, and guidelines received from
China and South Korea as well as some European countries include
the following advice:
(1) Oxygen therapy represents the main treatment intervention
for patients with severe infection. Mechanical ventilation
may be required in cases of respiratory failure refractory to
oxygen therapy [17].
(2) Chloroquine and its derivatives (Hydroxy-chloroquine), in
tablet form, have been suggested for those infected with the
coronavirus. The outcomes with chloroquine have indicated
a certain therapeutic effect in reducing the recovery period,
and decreasing the time spent in the hospital. Chloroquine is
a drug that has been widely used since 1945 as an anti-
malaria treatment and remedy for various other conditions
such as autoimmune diseases, amoebiasis, and HIV. Its main
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obtained globally, and it can be taken by pregnant woman as
well as nursing mothers with no substantial side effects [18].
Chloroquine was developed in 1934 by Bayer and is an amine
acidotropic form of quinine. Nonetheless, quinine was being
extracted from the bark of Cinchona trees in Peru for use as a
treatment for malaria long before chloroquine was discovered.
Hydroxychloroquine is a derivative of chloroquine that contains a
hydroxyl group attached to the side chain and is used as an anti-
malarial drug, while another derivative of chloroquine, 4-
aminoquinoline, has an amino-functional group in its structure.
However, using chloroquine and hydroxychloroquine for self-
treatment is not recommended [19,20].
(3) Arbidol, which has been used to treat influenza virus in-
fections, has also been reported to act as a coronavirus
infection inhibitor at 10e30 mM concentrations.
(4) Favipiravir is another antiviral drug that can be used against
novel influenza strains and a broad range of RNA viruses.
Correspondingly, clinical trials are being conducted to assess
its effectiveness in treating SARS-COV-2. Once in the cells,
favipiravir will convert to its active phosphoribosylated form
which is recognized as a substrate by the viral RNA-
dependent polymerase RNA, leading to a decrease in the
activity of RNA polymerase [14,21,22].
(5) Lopinavir-ritonavir has also been mentioned in the literature
as having been used for the inhibition of SARS-COV-2. Ac-
cording to Lim et al. [23], this drug was given to a COVID-19
infected patient in Korea, at a dosage of 2 tablets per day.
After just one day there was virtually no evidence of coro-
navirus titers plus a considerable reduction of the b-coro-
navirus viral loads. However, more work is necessary to
determine the direct influence of lopinavir-ritonavir on
remedying COVID-19 infection.
(6) Baricitinib is another drug suggested both for reducing
COVID-19 infections and inflammations [24].
(7) Mixing azithromycin with hydroxyquinone was examined in
French patients, and a significant decrease in the viral load
was observed at day-6 [25].
(8) Corticosteroids have commonly been used to repress
upraised cytokine levels in patients with SARS-CoV [26], and
MERS-CoV [27], but are not recommended for systemic use
in treating SARS-CoV-2 infected patients [28].
Additionally, the National Health Commission (NHC) of the
People's Republic of China reported that 60,107 confirmed COVID-
19 patients (85.20% of total confirmed cases) had been treated
with traditional Chinese medicine [29].
In natural-based therapy, two compounds in the library were
found to be inhibitive of SARS-COV, namely tannic acid
(IC50 ¼ 3 mM) and 3-isothealfavin-3-gallate (TF28) (IC50 ¼ 7 mM)
[30]. These two compounds belong to a group of natural poly-
phenols found in different kinds of tea including black and green
tea [31,32].
There are about 200 viruses that are sources of infection and
produce clinical syndromes that include a cough. Parainfluenza,
rhinoviruses, influenza, and corona viruses are the main viruses
that cause respiratory disease [2]. In earlier years, the Kurdish
people used quince and its leaves as a medicinal plant to treat a
strong cough by boiling it in water, and it was found to have a huge
impact as a cough inhibiter. The biological influence and chemical
structure of quince have been reported, and the leaves of quince
have been found to contain bioactive phytochemicals which
include phenolic compounds. Conjugated double bonds are presentin both quince leaves and chloroquine structure. In the case of
quince leaves, three different functional groups can be observed,
namely alcohol, ether, and ketone, while in the chloroquine struc-
ture several amine groups can be found [33].
Furthermore, the black seed is used for various pharmaceutical
and nutritional purposes, and the oil extracted from the black seed
has been scientifically proven to include many natural ingredients,
for instance, vitamins, carbohydrates, folic acid and proteins.
Additionally, the seeds’ oil contains thymoquinone and derivatives
that have been used as a remedy for several diseases, especially
asthma, headache, and as an anti-inflammatory, antioxidant, anti-
microbial and antidiabetic [34].
Recently, the Food and Drug Administration (FDA) has allowed
physicians across the country to start using antibody-rich plasma
extracted from the blood of those who have recovered from the
disease. Approval was given on March 24, 2020, under new emer-
gency protocols, for blood donated by coronavirus survivors to be
used to treat patients who are critically sick with the virus. Some
experts have argued that this could be the best possibility for
combating the coronavirus until more sophisticated therapies can
be developed, which could take several months.
6. Epidemiology and protection
Kurdistan is a region located in the north of Iraq and has a long
border with Iran. On February 19, 2020, the first case of infection
with a novel coronavirus was announced in Iran and the Kurdistan
government started to issue strict warnings to its citizens. However,
people from Kurdistan visit Iran for many different reasons, such as
medical treatment, tourism, business and there are a lot of students
from Kurdistan studying in Iran's universities. The government, in
coordinationwith other organizations and media outlets, started to
spread awareness and instructions to protect its citizens against
coronavirus disease. In this period, the Kurdistan regional govern-
ment (KRG) made the following decisions:
1 From the outset, to close the border with neighboring countries.
2 To quarantine all returnees from abroad for about 14 days.
3 The first COVID-19 infected case in Kurdistan was recorded on
March 1, 2020 in the city of Sulaymaniyah. The patient was an
old man that had visited Iran for medical treatment. After that,
efforts were intensified by health teams and government-run
security agencies until all citizens were quarantined in their
homes and traffic was blocked in all directions, to prevent the
virus's spread.
4 So far, 76 cases of the virus have been reported, with most of the
sources being people who have returned from abroad. The KRG
and health teams aim to test the relatives and close contacts of
the infected patients.
5 A pharmaceutical factory in the city of Sulaymaniyah has begun
preparations to produce a combination of both chloroquine and
azithromycin products, which are theoretically considered as
two common anti-coronavirus drugs available in the region [35].
For protection of health care workers such as doctors, nurses,
pharmacists, medical staff and other staff working in hospitals and
health sectors, the provision of personal protective equipment
(PPE) is vital. It is the government's responsibility to provide for all
those needs; however, a lack of PPE has emerged as a serious
problem in many countries. Since such countries cannot immedi-
ately acquire the necessary equipment, international efforts are
required to protect the safety of health care workers [36,37].
Moreover, collaboration between countries is necessary in order to
achieve international readiness to detect, prevent, and respond to
future outbreaks such as the coronavirus pandemic [38].
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There have so far been over 6,000,000 cases globally, and more
than 375,000 of those have died, whereas 2,900,000 have recov-
ered. According to the data, the global death rate has reached nearly
6%, and the recovery rate is around 45% (Fig. 2). Six months after the
onset of the outbreak of this virus, it is interesting to note that
China has reported 83,017 infected cases, 4634 deaths, and 78,307
recoveries. It can be observed that the death rate in China is about
5.5%, and the recovery rate among infected people is 94.3%. The
Chinese data therefore indicates that over time the number of re-
coveries will increase. As is known, in Iran, a neighboring country of
Kurdistan, the outbreak of the virus occurred earlier than in the
European countries, and it can be seen that Iran's recovery rate is
approximately 78%, which is much higher than in European
countries, Brazil, and the United States [39].
COVID-19 infection is a fast spreading viral disease that is
especially deadly for patients with a previous immunodeficiency. In
Iraqi Kurdistan, as our study area, until today 714 positive cases
have been reported by the ministry of health of Kurdistan Region
Government/Iraq. Among these cases only eight have died, six of
whom were male, all were aged between 37 and 75 years, and all
had previous history of a chronic disease such as diabetes, hyper-
tension, heart disease, and hypercholesteremia, which are major
risk factors for COVID-19 infection. Among other cases, including all
ages, some of them required oxygen ventilation intervention, and
most of them recovered, while the rest are experiencing fewer
symptoms and suffering from the infection compared to other
positive cases of COVID-19 infection in the rest of Iraq, neighboringFig. 2. Provides a breakdown of total cases, deaths, recoveries, active cases, acountries, and globally. This interesting finding may be related to
patients having strong immune systems because they do not have a
history of alcohol or drug use or chronic disease; alternatively, it
may be due to genetic profile differences. Many factors can lead to
immunodeficiency in a patient, such as old age, concomitant dis-
eases (diabetes, renal with liver failure, solid and hematologic
neoplasia, malnutrition, autoimmune diseases, and organ trans-
plant), as well as therapies such as corticosteroid, cytotoxic agents,
and stress [40e42]. Alcohol is responsible for causing widespread
health problems which increase incidence of infectious diseases
[43]. The chronic and acute use of alcohol is harmful to health and
can directly lead to suppression of various immune responses [44].
Phagocytic cells such as macrophage and neutrophils have an
important role in finding, ingesting, and killing microorganisms
that enter the body, while in people with chronic alcoholism the
activity of phagocytic cells is reduced [40]. Additionally, abuse of
drugs such as marijuana, cocaine, opiates, alcohol and nicotine can
cause changes in neuropsychological, pathophysiological, and im-
mune function responses by increasing susceptibility to infectious
diseases. It can be concluded that among the reasons for the
speedier recovery of positive cases, with less suffering, in Iraqi
Kurdistan is that they have an active immune system that has not
been exposed to such as chronic disease, alcoholism, and chronic
medication.
Some Kurdish citizens have spoken of the epidemic late last year
that had similar symptoms to those of the coronavirus. The strength
of the Kurdish community's immunity against COVID-19 infection
may be related to overcoming last year's epidemic which resulted
in the illness and death of many residents.nd serious cases for (a) KRG/Iraq, (b) Iraq, and (c) Throughout the world.
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Until now various countries have regarded quarantine as the
best method for stopping the distribution of COVID-19 infection.
The Kurdistan regional government (KRG) has so far successfully
coped with the coronavirus infection. Based on various reports,
people who have a strong immune system can more easily over-
come the COVID-19 infection. This mini-review has mentioned
some medicinal plants which are well known to boost the immune
system, such as black seed and the quince plant and its leaves.
Patients with a history of chronic disease, alcoholism, and drugs
have beenmore affected by the COVID-19 infection. It can therefore
be concluded that the immune system has a great influence on
recovery from the coronavirus. Meanwhile, stress, anxiety, fear, and
nervousness are among other main causes of lowering of the im-
mune system and greater vulnerability to catching this disease.
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